drugset / Trial / NCT00486291

Study of VI-0521 Compared to Placebo in the Glycemic Management of Obese Diabetics

NCT00486291

Phase 2 Completed 210 enrolled VIVUS LLC Synteract, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of VI-0521 compared to placebo in the glycemic management of obese diabetic adults.

Timeline

Start
2007-06
Primary completion
2008-04
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Phentermine Small molecule 15 mg
Subject Topiramate Small molecule 100 mg